Уважаемые коллеги, доброго времени суток! Представляем вам швейцарское научное издание Journal of Intensive Care. Журнал имеет первый квартиль, издаётся в Springer International Publishing AG, находится в открытом доступе, его SJR за 2021 г. равен 1,235, импакт-фактор 7,520, электронный ISSN - 2052-0492, предметные области - Интенсивная терапия и медицина, Реаниматология. Вот так выглядит обложка:
Редактором является Юшифуми Котаке, контактные данные - ykotake@med.toho-u.ac.jp.
Это журнал открытого доступа, охватывающий все аспекты медицины интенсивной терапии, такие, как интенсивная и критическая терапия, травматологическая и хирургическая интенсивная терапия, педиатрическая интенсивная терапия, острая и неотложная медицина, периоперационная медицина, реанимация, инфекционный контроль и дисфункция органов. Кроме того, журнал поощряет публикации, рассматривающие различные культурные аспекты практики интенсивной терапии.
Адрес издания - https://jintensivecare.biomedcentral.com/
Пример статьи, название - Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study. Заголовок (Abstract)
Background
Tigecycline has in vitro bacteriostatic activity against a broad spectrum of bacteria, including carbapenem-resistant Gram-negative bacteria (CR-GNB). However, the role of tigecycline in treatment of nosocomial pneumonia caused by CR-GNB remains controversial and clinical evidences are limited. We aimed to investigate the clinical benefits of tigecycline as part of the combination treatment of nosocomial CR-GNB pneumonia in intensive care unit (ICU).
Methods
This multi-centre cohort study retrospectively enrolled ICU-admitted patients with nosocomial pneumonia caused by CR-GNB. Patients were categorized based on whether add-on tigecycline was used in combination with at least one anti-CR-GNB antibiotic. Clinical outcomes and all-cause mortality between patients with and without tigecycline were compared in the original and propensity score (PS)-matched cohorts. A subgroup analysis was also performed to explore the differences of clinical efficacies of add-on tigecycline treatment when combined with various anti-CR-GNB agents.
Results
We analysed 395 patients with CR-GNB nosocomial pneumonia, of whom 148 received tigecycline and 247 did not. More than 80% of the enrolled patients were infected by CR-Acinetobacter baumannii (CRAB). A trend of lower all-cause mortality on day 28 was noted in tigecycline group in the original cohort (27.7% vs. 36.0%, p = 0.088). In PS-matched cohort (102 patient pairs), patients with tigecycline had significantly lower clinical failure (46.1% vs. 62.7%, p = 0.017) and mortality rates (28.4% vs. 52.9%, p < 0.001) on day 28. In multivariate analysis, tigecycline treatment was a protective factor against clinical failure (PS-matched cohort: aOR 0.52, 95% CI 0.28–0.95) and all-cause mortality (original cohort: aHR 0.69, 95% CI 0.47–0.99; PS-matched cohort: aHR 0.47, 95% CI 0.30–0.74) at 28 days. Kaplan–Meier survival analysis in subgroups of patients suggested significant clinical benefits of tigecycline when added to a colistin-included (log rank p value 0.005) and carbapenem-included (log rank p value 0.007) combination regimen.
Conclusions
In this retrospective observational study that included ICU-admitted patients with nosocomial pneumonia caused by tigecycline-susceptible CR-GNB, mostly CRAB, tigecycline as part of a combination treatment regimen was associated with lower clinical failure and all-cause mortality rates.